Serum Complement C3f and Fibrinopeptide A Are Potential Novel Diagnostic Biomarkers for Non-Alcoholic Fatty Liver Disease: A Study in Qingdao Twins. Here, FGA is linked to metabolic dysfunction-associated steatotic liver disease.